Eli Lilly and Company





Real-time Estimate Cboe BZX 10:12:24 2024-06-21 am EDT 5-day change 1st Jan Change
883.6 USD -0.27% Intraday chart for Eli Lilly and Company +0.35% +51.23%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Eli Lilly Sues More Wellness Centers, Medical Spas Over Unauthorized Tirzepatide Sales MT
Health Care Stocks Rise Behind Gilead -- Health Care Roundup DJ
Sector Update: Health Care Stocks Higher Late Afternoon MT
Sector Update: Health Care MT
Eli Lilly to 'Continue to Pursue Legal Remedies' Over Tirzepatide Product Claims MT
Eli Lilly Calls Out Unsafe Practices Involving Diabetes, Obesity Drugs MT
Eli Lilly Files More Lawsuits at Sellers of Counterfeit Mounjaro, Zepbound DJ
Eli Lilly: warning about counterfeit products CF
Central bank bonanza Our Logo
Lilly files additional lawsuits over US sales of counterfeit Mounjaro RE
Food companies with Ozempic-friendly snacks and meals wade carefully into weight-loss waters RE
A weight loss ETF MT
Health Care Flat as Traders Wait More Obesity-Drug Updates - Health Care Roundup DJ
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup DJ
Investors need more time to assess Fed comments Our Logo
Musk wins pay approval but still faces Tesla's floundering stock and rich valuation RE
Employer coverage for weight-loss drugs rises sharply, survey finds RE
Eli Lilly Gets FDA Approval for Selpercatinib to Treat Thyroid Cancer MT
Novo Nordisk, Eli Lilly's Weight-Loss Drugs Coverage Dropped by Blue Cross Blue Shield of Michigan MT
Biogen executive plays down looming competition for its Alzheimer's drug RE
Social Buzz: Wallstreetbets Stocks Mixed Premarket Wednesday; Oracle to Advance, AST SpaceMobile to Open Lower MT
Alzheon, Inc Announces Appointment of Gino Santini to Board of Directors CI
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Decline Tuesday Afternoon MT
Chart Eli Lilly and Company
More charts
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
886 USD
Average target price
855.4 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. News Eli Lilly and Company
  5. Sector Update: Health Care Stocks Gain in Afternoon Trading